Increased susceptibility to skin carcinogenesis in TREX2 knockout mice

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6676-6684

  Parra, David ^a   Manils, Joan ^a   Castellana, Bàrbara ^a   Viña Vilaseca, Arnau ^a   Morán Salvador, Eva ^a   Vázquez Villoldo, Nuria ^a   Tarancón, Gemma ^a   Borràs, Miquel ^a   Sancho, Sara ^b   Benito, Carmen ^a   Ortega, Sagrario ^c   Soler, Concepció ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Promed   (Switzerland)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; EXONUCLEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; CONTROLLED STUDY; EPIDERMIS; ESOPHAGUS; EXON; FEMALE; GENE; GENOME; GENOTOXICITY; KERATINOCYTE; KNOCKOUT MOUSE; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SQUAMOUS EPITHELIUM; SURVIVAL; TREX2 GENE; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; AGING; ANIMALS; APOPTOSIS; CARCINOGENS; CARCINOMA; CELLS, CULTURED; EMBRYO, MAMMALIAN; EXODEOXYRIBONUCLEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SPECIFICITY; SKIN NEOPLASMS; TISSUE DISTRIBUTION;

EID: 69249141369     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1208     Document Type: Article

References (44)

1. Shevelev IV, Hubscher U. The 3′ 5′ exonucleases. Nat Rev Mol Cell Biol 2002;3:364-76.
2. Burkovics P, Szukacsov V, Unk I, Haracska L. Human Ape2 protein has a 3′-5′ exonuclease activity that acts preferentially on mismatched base pairs. Nucleic Acids Res 2006;34:2508-15.
3. Kaetzel DM, Zhang Q, Yang M, McCorkle JR, Ma D, Craven RJ. Potential roles of 3′-5′ exonuclease activity of NM23-1 in DNA repair and malignant progression. J Bioenerg Biomembr 2006;38:163-7.
4. Masuda-Sasa T, Imamura O, Campbell JL. Biochemical analysis of human Dna2. Nucleic Acids Res 2006;34: 1865-75.
5. Lilling G, Elena N, Sidi Y, Bakhanashvili M. p53-associated 3′->5′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 2003;22: 233-45.
6. Goldsby RE, Hays LE, Chen X, et al. High incidence of epithelial cancers in mice deficient for DNA polymerase y proofreading. Proc Natl Acad Sci U S A 2002;99: 15560-5.
7. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004;429:417-23.
8. Ide Y, Tsuchimoto D, Tominaga Y, et al. Growth retardation and dyslymphopoiesis accompanied by G2-M arrest in APEX2-null mice. Blood 2004;104:4097-103.
9. Wei K, Clark AB, Wong E, et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 2003;17:603-14.
10. Hopkins KM, Auerbach W, Wang XY, et al. Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol 2004;24:7235-48.
11. Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3′->5′ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004;24:6719-27.
12. Mazur DJ, Perrino FW. Excision of 3′ termini by the Trex1 and TREX2 3′->5′ exonucleases. Characterization of the recombinant proteins. J Biol Chem 2001;276: 17022-9.
13. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J 1999;18:3868-75.
14. Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′->5′ exonucleases. J Biol Chem 1999;274: 19655-60.
15. Shevelev IV, Ramadan K, Hubscher U. The TREX2 3′->5′ exonuclease physically interacts with DNA polymerase y and increases its accuracy. Sci World J 2002;2:275-81.
16. de Silva U, Choudhury S, Bailey SL, Harvey S, Perrino FW, Hollis T. The crystal structure of TREX1 explains the 3′ nucleotide specificity and reveals a polyproline II helix for protein partnering. J Biol Chem 2007;282: 10537-43.
17. Perrino FW, Harvey S, McMillin S, Hollis T. The human TREX2 3′->5′-exonuclease structure suggests a mechanism for efficient nonprocessive DNA catalysis. J Biol Chem 2005;280:15212-8.
18. Perrino FW, de Silva U, Harvey S, Pryor EE, Jr., Cole DW, Hollis T. Cooperative DNA binding and communication across the dimer interface in the TREX2 3′->5′-exonuclease. J Biol Chem 2008;283:21441-52.
19. de Silva U, Perrino FW, Hollis T. DNA binding induces active site conformational change in the human TREX2 3′-exonuclease. Nucleic Acids Res 2009;37:2411-7.
20. Chen MJ, Ma SM, Dumitrache LC, Hasty P. Biochemical and cellular characteristics of the 3′->5′ exonuclease TREX2. Nucleic Acids Res 2007;35:2682-94.
21. Chowdhury D, Beresford PJ, Zhu P, et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006;23:133-42.
22. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007;131:873-86.
23. Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006;38:917-20.
24. Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065-7.
25. Richards A, van den Maagdenberg AM, Jen JC, et al. C-fsterminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007;39: 1068-70.
26. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008;134:587-98.
27. Chen MJ, Dumitrache LC, Wangsa D, et al. Cisplatin depletes TREX2 and causes Robertsonian translocations as seen in TREX2 knockout cells. Cancer Res 2007;67: 9077-83.
28. Dumitrache LC, Hu L, Hasty P. TREX2 exonuclease defective cells exhibit double-strand breaks and chromosomal fragments but not Robertsonian translocations. Mutat Res 2009;662:84-7.
29. Soler C, Garcia-Manteiga J, Valdes R, et al. Macrophages require different nucleoside transport systems for proliferation and activation. Faseb J 2001;15:1979-88.
30. Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev 2007;21: 206-20.
31. Mazur DJ, Perrino FW. Structure and expression of the TREX1 and TREX2 3′->5′ exonuclease genes. J Biol Chem 2001;276:14718-27.
32. Haines DC, Chattopadhyay S, Ward JM. Pathology of aging B6;129 mice. Toxicol Pathol 2001;29:653-61.
33. Friedberg EC, Meira LB. Database of mouse strains carrying targeted mutations in genes affecting biological responses to DNA damage Version 7. DNA Repair (Amst) 2006;5:189-209.
34. Nakane H, Takeuchi S, Yuba S, et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature 1995;377:165-8.
35. Sands AT, Abuin A, Sanchez A, Conti CJ, Bradley A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 1995;377:162-5.
36. Hirao A, Cheung A, Duncan G, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATMindependent manner. Mol Cell Biol 2002;22:6521-32.
37. Stracker TH, Couto SS, Cordon-Cardo C, Matos T, Petrini JH. Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol Cell 2008; 31:21-32.
38. Yan B, Wang H, Peng Y, et al. A unique role of the DNA fragmentation factor in maintaining genomic stability. Proc Natl Acad Sci U S A 2006;103:1504-9.
39. Kemp CJ, Vo K, Gurley KE. Resistance to skin tumorigenesis in DNAPK-deficient SCID mice is not due to immunodeficiency but results from hypersensitivity to TPA-induced apoptosis. Carcinogenesis 1999;20: 2051-6.
40. de Waard H, Sonneveld E, de Wit J, et al. Cell-typespecific consequences of nucleotide excision repair deficiencies: embryonic stem cells versus fibroblasts. DNA Repair (Amst) 2008;7:1659-69.
41. Attardi LD. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res 2005;569:145-57.
42. Spillare EA, Robles AI, Wang XW, et al. p53-mediated apoptosis is attenuated in Werner syndrome cells. Genes Dev 1999;13:1355-60.
43. Quigley DA, To MD, Perez-Losada J, et al. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 2009;458:505-8.
44. Liu B, Xia X, Zhu F, et al. IKKa is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell 2008;14:212-25.